lgd-4033
ANABOLIC · NONSTEROIDAL SARM · ORAL · T½ 24–36 H
also: ligandrol · VK5211 · anabolicum
LGD-4033 has one published randomised phase 1 human trial establishing short-term tolerability, dose-proportional pharmacokinetics and dose-dependent lean mass increase over three weeks. Beyond that single 21-day study there is no published human efficacy data, no long-term safety data, and no regulatory approval in any jurisdiction.
// our evidence grade — unedited
A single well-conducted 21-day phase 1 safety and PK study in 76 healthy men is the entire published human evidence base, and it was a safety study never designed to demonstrate clinical benefit.
We grade this compound and we sell it. The grade is set against our published criteria before any stocking decision and is not adjusted because it is in the catalogue.
read the full evidence →// specification
| full name | LGD-4033 (ligandrol, VK5211) |
| cas | 1165910-22-4 |
| formula | C14H12F6N2O |
| molar mass | 338.25 g/mol |
| purity | ≥ 98% HPLC |
| form | research solution |
| storage | Reference material: store as a solid, desiccated and protected from light, at -20 °C for long-term stability; stock solutions typically stored at -80 °C with freeze-thaw cycles minimised. |
| solubility | Lipophilic small molecule; soluble in DMSO and ethanol, poorly soluble in water. Lot-specific solubility should be taken from the certificate of analysis. |
// select size
crypto payment · research use only · not for human consumption
// others in Anabolic & Receptor